ARDS vs. BPTS, NBY, ARAV, CYCC, ATXI, CLVR, AGRX, SXTP, ONCO, and VRPX
Should you be buying Aridis Pharmaceuticals stock or one of its competitors? The main competitors of Aridis Pharmaceuticals include Biophytis (BPTS), NovaBay Pharmaceuticals (NBY), Aravive (ARAV), Cyclacel Pharmaceuticals (CYCC), Avenue Therapeutics (ATXI), Clever Leaves (CLVR), Agile Therapeutics (AGRX), 60 Degrees Pharmaceuticals (SXTP), Onconetix (ONCO), and Virpax Pharmaceuticals (VRPX). These companies are all part of the "pharmaceutical preparations" industry.
Biophytis (NASDAQ:BPTS) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends, risk and profitability.
Biophytis has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500.
Biophytis has higher earnings, but lower revenue than Aridis Pharmaceuticals.
Biophytis has a net margin of 0.00% compared to Biophytis' net margin of -5.11%.
Aridis Pharmaceuticals received 116 more outperform votes than Biophytis when rated by MarketBeat users. However, 100.00% of users gave Biophytis an outperform vote while only 61.00% of users gave Aridis Pharmaceuticals an outperform vote.
In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.
0.1% of Biophytis shares are held by institutional investors. Comparatively, 9.7% of Aridis Pharmaceuticals shares are held by institutional investors. 3.7% of Biophytis shares are held by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Biophytis presently has a consensus target price of $600.00, indicating a potential upside of ∞. Aridis Pharmaceuticals has a consensus target price of $2.00, indicating a potential upside of 3,439.82%. Given Aridis Pharmaceuticals' higher probable upside, equities research analysts plainly believe Biophytis is more favorable than Aridis Pharmaceuticals.
Summary
Biophytis and Aridis Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.
Get Aridis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aridis Pharmaceuticals Competitors List
Related Companies and Tools
